ClinicalTrials.gg
RecruitingNCT04776005COVIDVAC OHUpdated Jan 3, 2024

COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies

An observational study in Solid Tumor, Hematologic Malignancy and Thoracic Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Assistance Publique - Hôpitaux de Paris.

Started
2021
the only one that year
Observational
7 of 16
3 open now
Registered
12th of 16
by date

Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2021, is one of 7 observational ones, and was the 12th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

6 of the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

In the context of malignant disease, it is likely that vaccine efficacy and immunogenicity depends on the type of pathology, stage of the disease, immunosuppression induced by the treatments, in addition to more classic factors such as age, general condition and possibly the type of vaccine used.

There are very little data on the efficacy and immunogenicity of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with malignant disease in the active phase of treatment.

This multicenter observational study aims to assess the efficacy and the immunogenicity of anti-Sars-CoV-2 vaccines in the cohort of patients treated for malignant pathology (solid or hematological tumors) at Saint Louis Hospital and in thoracic oncology patients at Bichat Hospital.

Read the detailed description

During the visit carried out as part of the follow-up, participation in this study will be proposed to any patient who is treated for a malignant disease (solid or hematological tumors) within the university hospitals of AP-HP.Nord.

The patients participating in this prospective cohort will benefit from all standard care his/her condition requires.

Clinical and biological data will be collected as part of the usual follow-up. Clinical data: pathology, stage, treatment line, type of current treatment and date of the last treatment administered, previous treatments, radiotherapy, concept of radiation lung disease, history of pneumonectomy, comorbidities, performance status, history of coronavirus disease 2019 (COVID-19).

Laboratory data: pre-vaccination polynuclear neutrophil count, lymphocyte counts, plasma protein electrophoresis or Ig weight dosage (routine care in hematology), lactate dehydrogenase (LDH), C-reactive protein (CRP), albuminemia in the previous month.

Vaccination data: type of vaccine, date of the 1st injection, date of the 2nd injection, pre-vaccination antibody levels

  • Seroconversion with anti-S IgG after anti-Sars-CoV-2 vaccination
  • Anti-S and / or anti-N Sars-CoV-2 IgG seroprevalence before vaccination
  • Adverse effects related to vaccines
  • Levels of the anti-S IgG antibodies in AU / ml

During visits between D21 and D28 (before the 2nd injection), at month 3, month 6 and month 12, the following data will be collected:

  • Antibody levels
  • Adverse effects related to vaccines
  • Levels of the anti-S IgG antibodies in AU / ml
  • Associated side effects
  • Occurrence of COVID-19.
03

Conditions studied

  • Solid Tumor
  • Hematologic Malignancy
  • Thoracic Cancer
  • Cancer, Treatment-Related
  • Vaccine Response Impaired

Keywords

  • Malignant pathology
  • Hematologic malignancy
  • COVID-19
  • Vaccine
  • Sars-CoV-2 antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are treated for a malignant disease (solid or hematological tumors) within the CHU AP-HP.Nord and who are willing to get a SARS-CoV-2 vaccination.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with malignant disease undergoing treatment at Saint Louis Hospital or Bichat Hospital (for chest cancer)
  • with chemotherapy
  • with chemotherapy + Immunotherapy
  • with immunotherapy
  • with targeted therapies
  • with radiotherapy
  • in the event of radiation pneumonitis after radiotherapy for lung cancers
  • after pneumonectomy for lung cancer
  • Patient informed and having expressed their non-opposition to participating in this research

Exclusion criteria

Exclusion Criteria:

  • Patient with a to Sars-Cov2 vaccination
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with malignant disease undergoing chemotherapy

    Patients with malignant disease undergoing chemotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

    Other: Data collection

  • Patients with malignant disease undergoing chemotherapy + immunotherapy

    Patients with malignant disease undergoing chemotherapy + immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

    Other: Data collection

  • Patients with malignant disease undergoing immunotherapy

    Patients with malignant disease undergoing immunotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

    Other: Data collection

  • Patients with malignant disease treated with targeted therapies

    Patients with malignant disease treated with targeted therapies within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

    Other: Data collection

  • Patients with malignant disease undergoing radiotherapy

    Patients with malignant disease undergoing radiotherapy within the University Hospital Centre AP-HP.Nord, who have voluntarily agreed to be vaccinated with an approved vaccine against the Sars-CoV-2 virus.

    Other: Data collection

Interventions

  • OtherData collection

    Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.

06

What researchers measure

Primary outcomes

  1. SARS-CoV-2 vaccine response at 12 months

    IgG anti-Sarc-CoV-2 S-protein titer at 12 months

    Time frame: 12 months

Secondary outcomes

  1. Seroprevalence of antibodies against Sarc-CoV-2 S-protein before vaccination

    Rate of patients presenting the anti Sarc-CoV-2 S-protein antibodies before vaccination in the study population.

    Time frame: Day 0

  2. Seroprevalence of antibodies against Sarc-CoV-2 N-protein before vaccination

    Rate of patients presenting the anti Sarc-CoV-2 N-protein antibodies before vaccination in the study population.

    Time frame: Day 0

  3. SARS-CoV-2 vaccine response after first dose of vaccine

    IgG anti-Sarc-CoV-2 S-protein titer after the first injection of vaccine

    Time frame: Day 24 +/- 4 days

  4. SARS-CoV-2 vaccine response at 3 months

    IgG anti-Sarc-CoV-2 S-protein titer at 3 months

    Time frame: 3 months

  5. SARS-CoV-2 vaccine response at 6 months

    IgG anti-Sarc-CoV-2 S-protein titer at 6 months

    Time frame: 6 months

  6. SARS-CoV-2 vaccine safety in the study population

    Occurence of the adverse events related to the SARS-CoV-2 vaccine

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Feb 2024, 37 months after the start.

Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 37 months is below that.

Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 1, 2021
StartActual
Jan 22, 2021
Primary completionEst.
Feb 2024
CompletionEst.
Feb 2024
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04776005
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Jan 22, 2021
Primary completion
Feb 2024 (estimated)
Completion
Feb 2024 (estimated)
Last update
Jan 3, 2024

Study contacts

Luis TEIXEIRA, MD, PhD
Contact
luis.teixeira@aphp.fr
+33 142499613
Luis TEIXEIRA, MD, PhD
principal investigator · Breast Disease Unit, Saint-Louis Hospital, APHP, Université de Paris, INSERM U976

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion